Prediction of myelotoxicity using semi-quantitative marrow image scores.

PubWeight™: 1.94‹?› | Rank: Top 3%

🔗 View Article (PMID 9374345)

Published in J Nucl Med on November 01, 1997

Authors

S Lim1, G L DeNardo, D A DeNardo, R T O'Donnell, A Yuan, S J DeNardo

Author Affiliations

1: University of California Davis Medical Center; and Veterans Administration Northern California Health Care System, Sacramento 95816, USA.

Articles by these authors

Slo3, a novel pH-sensitive K+ channel from mammalian spermatocytes. J Biol Chem (1998) 2.19

Collapsin response mediator protein-1 and the invasion and metastasis of cancer cells. J Natl Cancer Inst (2001) 2.17

Transplantable sites confer calcium sensitivity to BK channels. Nat Neurosci (1999) 2.04

Radioassay of yttrium-90 radiation using the radionuclide dose calibrator. J Nucl Med (1997) 1.68

Clinical assessment of left ventricular regional contraction patterns and ejection fraction by high-resolution gated scintigraphy. J Nucl Med (1975) 1.48

High-affinity L-arabinose transport operon. Nucleotide sequence and analysis of gene products. J Mol Biol (1987) 1.46

Spontaneous pneumothorax associated with ankylosing spondylitis. Rheumatology (Oxford) (2005) 1.46

The ventilatory lung scan in the diagnosis of pulmonary embolism. N Engl J Med (1970) 1.44

131I-Lym-1 in mice implanted with human Burkitt's lymphoma (Raji) tumors: loss of tumor specificity due to radiolysis. Cancer Biother Radiopharm (2000) 1.39

Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. Anal Biochem (1985) 1.33

Differentiation of benign and malignant cervical lymph nodes with color Doppler sonography. AJR Am J Roentgenol (1994) 1.20

Preventable deaths in patients admitted from emergency department. Emerg Med J (2006) 1.18

Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice. J Nucl Med (1988) 1.17

Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung. J Nucl Med (1994) 1.15

NanoFerrite particle based radioimmunonanoparticles: binding affinity and in vivo pharmacokinetics. Bioconjug Chem (2008) 1.11

Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Cancer (1997) 1.11

A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Cancer (1994) 1.09

Potential use of amino acid cocktails to reduce renal tubular reabsorption of radioconjugates. J Nucl Med (1996) 1.08

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol (1998) 1.07

Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice. Cancer Biol Ther (2008) 1.07

Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res (1995) 1.06

Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci U S A (1997) 1.04

Scintigraphy in the diagnosis of osteonecrosis. Clin Orthop Relat Res (1978) 1.02

Review of a 5-year experience with the radiostrontium bone scintiscan. Calif Med (1972) 1.02

Evolution tunes the excitability of individual neurons. Neuroscience (2001) 1.02

Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy. Cancer Biother Radiopharm (2001) 1.01

Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy. J Nucl Med (1988) 1.01

Serum stability of 67Cu chelates: comparison with 111In and 57Co. Int J Rad Appl Instrum B (1986) 1.00

Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients. Nucl Med Biol (1999) 0.99

Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med (1990) 0.97

Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. Cancer Biother Radiopharm (1998) 0.96

Radioimmunotherapy: recent results and future directions. J Clin Oncol (1996) 0.96

Assessment of conventional criteria for the early diagnosis of thrombophlebitis with the 125I-fibrinogen uptake test. Radiology (1977) 0.96

Scintigraphic imaging of a blind-ending ureteral duplication. J Nucl Med (1975) 0.96

67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. Clin Cancer Res (1999) 0.94

Comparative serum stability of radiochelates for antibody radiopharmaceuticals. J Nucl Med (1987) 0.94

Blood flow in irradiated mouse sarcoma as determined by the clearance of xenon-133. Cancer Res (1972) 0.94

Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies. Crit Rev Oncol Hematol (2001) 0.94

Vascularity of the femoral head. Tc diphosphonate scintigraphy validated with tetracycline labeling. Clin Orthop Relat Res (1977) 0.94

Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer Suppl (1990) 0.93

Dissection of K+ currents in Caenorhabditis elegans muscle cells by genetics and RNA interference. Proc Natl Acad Sci U S A (2003) 0.93

Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Nucl Med (1999) 0.93

85 Sr bone scan in neoplastic disease. Semin Nucl Med (1972) 0.93

Stable bifunctional chelates of metals used in radiotherapy. Cancer Res (1990) 0.93

Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3). Cancer (1994) 0.92

Quantitative bremsstrahlung imaging of yttrium-90 using a Wiener filter. Med Phys (1994) 0.92

Radionuclide assessment of nitroglycerin influence on abnormal left ventricular segmental contraction in patients with coronary heart disease. Circulation (1976) 0.91

The 85-Sr scintiscan in bone disease. Ann Intern Med (1966) 0.91

Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med (1999) 0.90

Dicarboxylic acid dipeptide neutral endopeptidase inhibitors. J Med Chem (1995) 0.90

Resolution of an early RecA-recombination intermediate by a junction-specific endonuclease. Proc Natl Acad Sci U S A (1997) 0.90

A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. J Nucl Med (1999) 0.90

Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy. Int J Rad Appl Instrum B (1991) 0.90

Antiangiogenic agents and their promising potential in combined therapy. Crit Rev Oncol Hematol (2001) 0.90

Vaginal deployment and tenofovir delivery by microbicide gels. Drug Deliv Transl Res (2015) 0.89

A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy. Nucl Med Biol (1996) 0.89

Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy. Cancer Biother Radiopharm (2001) 0.88

Hepatic scintiangiographic patterns. Radiology (1974) 0.88

Sodium flux in myotonic muscular dystrophy. Am J Physiol (1968) 0.88

Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies. Int J Cancer Suppl (1988) 0.87

Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing. Crit Rev Oncol Hematol (2001) 0.87

Critical evaluation of hepatic scintiangiography for neoplastic tumors of the liver. J Nucl Med (1975) 0.87

New approach to interpretation of technetium-99m pyrophosphate scintigraphy in detection of acute myocardial infarction: clinical assessment of diagnostic accuracy. Am J Cardiol (1977) 0.87

Origin and evolution of radioactive pulmonary emboli in man. Radiology (1968) 0.86

Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. Cancer Biother Radiopharm (2000) 0.85

L6 monoclonal antibody binds prostate cancer. Prostate (1998) 0.85